Treatment of enzalutamide-resistant prostate cancer cells with the GSI, PF-03084014, or an alternative specific gene knockdown of Notch 1, resensitised cells to enzalutamide treatment, while the drug combination showed efficacy in xenograft models [90]. This evidence concerns the gene NOTCH1 and Familial prostate cancer.